Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 14/20 | 0.77 |
| ▸ | GSK3B | P49841 | 7/20 | 0.70 |
| ▸ | CCNE1 | P24864 | 8/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12953491 | 0.87 | CDK2 (1.00) | CDK2GSK3BCCNE1 | |
| SCHEMBL12954111 | 0.86 | CDK2 (0.74) | CDK2GSK3BCCNE1 | |
| SCHEMBL12953207 | 0.86 | CDK2 (0.79) | CDK2GSK3BCCNE1 | |
| SCHEMBL12953189 | 0.86 | GSK3B (0.71) | CDK2GSK3BCCNE1 | |
| SCHEMBL12953191 | 0.84 | CDK2 (0.82) | CDK2GSK3BCCNE1 | |
| SCHEMBL12952859 | 0.82 | GSK3B (1.00) | CDK2GSK3BCCNE1 | |
| SCHEMBL30263731 | 0.82 | GSK3B (1.00) | CDK2GSK3BCCNE1 | |
| SCHEMBL12953598 | 0.82 | CDK2 (0.78) | CDK2GSK3BCCNE1 | |
| SCHEMBL12953036 | 0.82 | CDK2 (0.74) | CDK2GSK3BCCNE1 | |
| SCHEMBL12953157 | 0.82 | CDK2 (0.81) | CDK2GSK3BCCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807683-B2 | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807683-B2 | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2010-10-05 | — | — | US | disclosed |
| US-20070054906-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-03-08 | — | — | US | disclosed |
| US-20070054906-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-03-08 | — | — | US | disclosed |
| US-20070037824-A1 | Enzyme inhibitors from pyrazolo[1,5a]pyrimidine as enzyme inhibitors | SCHERING CORPORATION | 2007-02-15 | — | — | US | disclosed |
| US-20070037824-A1 | Enzyme inhibitors from pyrazolo[1,5a]pyrimidine as enzyme inhibitors | SCHERING CORPORATION | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037824-A1 | Enzyme inhibitors from pyrazolo[1,5a]pyrimidine as enzyme inhibitors | CDK2, CDK5, CDKN1A | CDK2 1/4885GSK3B 937/4885CCNE1 40/4885 |
| US-20070054906-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDK1, CDKN1A | CDK2 1/4885GSK3B 695/4885CCNE1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.